ArticleClinical journal of gastroenterology2026
Endocrine carcinoma with amphicrine carcinoma component at esophagogastric junction.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amphicrine carcinoma is a rare malignancy exhibiting both endocrine and exocrine differentiation within the same tumor cells. We report a case of a 70-year-old male who underwent screening upper endoscopy, which revealed a 15 mm depressed lesion with a reddish elevated margin at the esophagogastric junction. Narrow-band imaging with magnification demonstrated an irregular, densely packed vascular pattern, suggesting malignancy. Endoscopic ultrasound indicated third-layer disruption, raising suspicion of submucosal invasion. Endoscopic resection was performed after informed consent. Histopathological analysis confirmed submucosal invasion and identified three tumor components: (1) an endocrine carcinoma component with a solid-nest structure, (2) a glandular component, and (3) a goblet cell-like signet ring cell carcinoma component. Immunohistochemistry revealed synaptophysin, INSM1, and CD56 positivity in all components, while MUC2 was expressed in the signet ring cell carcinoma component and partially in the others. The tumor exhibited a high Ki-67 labeling index, indicating aggressive proliferation. Based on these findings, the lesion was diagnosed as an endocrine carcinoma with an amphicrine carcinoma component. Additional surgery confirmed no residual tumor or lymph node metastasis. Given the rarity of amphicrine carcinoma and the limited understanding of its clinical behavior, further research is necessary to determine its prognosis and optimal management strategies.
Indexed as
Identifiers
41691558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.